Interventional Cardiovascular Surgery

This prespecified analysis of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME 3) trial examined the impact on cardiovascular outcomes of treatment by CABG versus FFR-guided PCI in patients with three vessel disease (3-VD), stratified by acute (NSTEMI) or chronic coronary syndrome (CCS) presentation.

The Andreas Grüntzig Ethica Award is traditionally given to those who have contributed in an extraordinary way to the PCR mission, that of serving the needs of patients by sharing knowledge, experience and practice in cardiovascular interventional medicine.

Kalaivani Mahadevan provides her take on the five-year outcomes of the FAME 3 trial presented by William F. Fearon at ACC.25 in Chicago.

Yohei Ohno provides his takeaways from the results of the Evolut Low Risk trial which was presented by Michael J. Reardon during the ACC.25 in Chicago.

Explore the latest strategies for optimizing outcomes in Asian and international patients with small body size. Through case presentations, surgical experiences, and the latest data on device performance, gain valuable insights into treating aortic stenosis more effectively. Discover how these advancements can enhance patient care and...

Complex procedures, such as TAVI in patients with a degenerated bioprosthesis and a Bentall surgery history, demand meticulous planning. This case highlights the importance of computed tomography imaging to minimize procedural risks and explores the snare strategy for navigating anatomical constraints. Learn how this approach, adaptable to...

This registry-based observational study compares surgical and percutaneous revascularization in patients with multivessel disease who underwent treatment for non-ST-segment elevation myocardial infarction (NSTEMI), utilizing data extracted from the SWEDEHEART registry.

The TCW trial found that FFR-guided PCI with TAVI offers favorable one-year outcomes, including lower rates of all-cause mortality, MI, disabling stroke, revascularisation, valve reintervention, and severe bleeding, compared to CABG with SAVR.

Wondering which is the better option for female patients—SAVR or TAVR? Don’t miss this exchange between Hendrik Treede and Hélène Eltchaninoff. They explore the unique challenges and nuances of valve interventions for women, highlighting evolving strategies to optimize treatment and improve outcomes.

You may also be interested...

Edoardo Zancanaro provides his take on the ENBALV trial presented by Chisato Izumi at AHA 2024 in Chicago.